lasmiditan Treatment for Migraine Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine INDIANAPOLIS, Nov. 14, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute treatment […]Continue Reading ...
Oct 23 2018 Novartis announced today that the full data from the LIBERTY study of Aimovig® (erenumab) in episodic migraine patients who had tried and failed two to four prior preventive treatments have been published in the Lancet. Patients treated with Aimovig had significant improvements on all primary and secondary endpoints of the study. Aimovig […]Continue Reading ...
By slightly changing the body’s own molecules using a small inhaler, certain migraine patients can either cut down on medication or do without it completely. This is shown by a pilot study which has been published in the scientific journal Cephalalgia. Patients who suffer from migraine with aura, which is where they experience either sensory […]Continue Reading ...
Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved AJOVYTM (fremanezumab-vfrm) injection for the preventive treatment of migraine in adults. AJOVY, a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor, is the first and only anti-CGRP treatment for […]Continue Reading ...
To decrease the substantial health and economic burden of migraine on individuals and society, researchers need to examine and address how the disease differs between women and men, according to a report from the Society for Women’s Health Research published in the August issue of the Journal of Women’s Health. Women shoulder a significant amount […]Continue Reading ...
INDIANAPOLIS, June 27, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today results from a post-hoc analysis which demonstrated efficacy of Emgality™ (galcanezumab-gnlm) in patients with episodic and chronic migraine who had previously failed preventive treatment with Botox®* (onabotulinumtoxinA). Detailed results from a post-hoc analysis of three Phase 3 studies (EVOLVE-1, EVOLVE-2 and […]Continue Reading ...
June 28, 2018 While it has been known that estrogen plays a role in migraine for women, new research shows that the female sex hormone may also play a role in migraine for men, according to a small study published in the June 27, 2018, online issue of Neurology®, the medical journal of the American […]Continue Reading ...
DUBLIN, June 11, 2018 /PRNewswire/ — Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, today announced positive results from CGP-MD-01, a Phase 2b/3 clinical trial evaluating the efficacy, safety, and tolerability of orally administered atogepant. All active treatment arms of atogepant met the primary endpoint across all doses and dose regimens, with a statistically […]Continue Reading ...
CHOP Researcher: Findings may suggest more effective headache treatments Pediatric researchers have discovered common gene variants associated with migraines in African-American children. The research adds to knowledge of genetic influences on childhood migraine and may lead to future precision medicine treatments for African-American children with these intense headaches. “Scientists already know that migraines may run […]Continue Reading ...
FDA Approves Emgality (galcanezumab-gnlm) for the Preventive Treatment of Migraine in Adults INDIANAPOLIS, Sept. 27, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg injection for the preventive treatment of migraine in adults.1 Emgality offers a once-monthly, self-administered, subcutaneous […]Continue Reading ...
FDA Approves Ajovy (fremanezumab-vfrm) for Preventive Treatment of Migraine September 14, 2018 — Today, the US Food and Drug Administration (FDA) approved Ajovy (fremanezumab-vfrm) for the preventive treatment of migraine in adults. Ajovy is the second FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related […]Continue Reading ...
August 14, 2018 Research published today reveals a potential mechanism for migraine causation which could explain why women get more migraines than men. The study, in Frontiers in Molecular Biosciences, suggests that sex hormones affect cells around the trigeminal nerve and connected blood vessels in the head, with estrogens — at their highest levels in […]Continue Reading ...
June 30, 2018 If you’ve ever had a migraine, you know it’s different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness. According to the Migraine Research Foundation, approximately 12% of people […]Continue Reading ...
June 27, 2018 When migraine sufferers see the tell-tale squiggly lines, light flashes and blind spots of a migraine aura, they prepare for a migraine. When researchers see the brain image of an aura, they try to figure out what causes it and if there is a way to stop the start of the migraine. […]Continue Reading ...
JERUSALEM–(BUSINESS WIRE)–May 15, 2018– Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the publication of data from the Phase III HALO study evaluating the efficacy, safety, and tolerability of both quarterly (every three months) and monthly subcutaneous dosing regimens of fremanezumab for the prevention of episodic migraine (EM). These pivotal data were published […]Continue Reading ...
- Dementia symptoms peak in winter and spring, study finds
- Stanford tobacco researcher weighs in on JUUL
- Researchers find no link between infants waking up at night and later developmental problems
- Both parents and children agree about confidential medical services
- FDA warns against use of unapproved pain medications with implanted pumps
- Precision medicine-based approach to slow or reverse biologic drivers of Alzheimer’s disease
- Study provides new insight into norovirus outbreaks, may help guide efforts to develop vaccines
- Inexpensive, portable air purifier could help protect the heart from pollution
- New 15-minute scan could help diagnose brain damage in babies up to two years old
- Deep brain stimulation not effective for treating early Alzheimer’s
- Traditional chemotherapy superior to new alternative for oropharyngeal cancers | News Center
- What This Pond Protist Does With Its Genome Will Astound You
- Researchers develop tool that speeds up analysis and publication of biomedical data
- Scientists identify mechanism used by lung cancer cells to obtain glucose
- Abnormalities in development of the brain could be involved in onset of autism, finds new study
- Soy protein equally effective as animal protein in building muscle strength
- American Academy of Pediatrics, Nov. 2-6
- Dopamine drives early addiction to heroin
- Variance in gut microbiome in Himalayan populations linked to dietary lifestyle | News Center
- Reducing Cardiovascular Disease: The Amish Way